Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754491 | 0.85 | CHRNA7 (0.43) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 | |
| SCHEMBL25758908 | 0.83 | GBA1 (0.42) | — | |
| SCHEMBL25839729 | 0.82 | HRH3 (0.47) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 | |
| SCHEMBL25785937 | 0.78 | CHRM2 (0.44) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 | |
| SCHEMBL25758913 | 0.73 | ALDH1A1 (0.46) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL13504063 | 0.73 | CHRNA7 (0.46) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 | |
| SCHEMBL2743291 | 0.73 | CHRM2 (0.68) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 | |
| SCHEMBL9298549 | 0.72 | ALDH1A1 (0.48) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL24112874 | 0.72 | HRH3 (0.46) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 | |
| SCHEMBL17896405 | 0.71 | CHRM2 (0.49) | CHRNB2CHRNA7CHRNA4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CHRNB2 4856/4885CHRNA7 4874/4885CHRNA4 4885/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CHRNB2 4841/4885CHRNA7 4866/4885CHRNA4 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.